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Human lactoferrin is a component of the non-specific immune system with distinct antiviral properties. We used alphaviruses, adapted to
interaction with heparan sulfate (HS), as a tool to investigate the mechanism of lactoferrin’s antiviral activity. Lactoferrin inhibited infection
of BHK-21 cells by HS-adapted, but not by non-adapted, Sindbis virus (SIN) or Semliki Forest virus (SFV). Lactoferrin also inhibited
binding of radiolabeled HS-adapted viruses to BHK-21 cells or liposomes containing lipid-conjugated heparin as a receptor analog. On the
other hand, low-pH-induced fusion of the viruses with liposomes, which occurs independently of virus-receptor interaction, was unaffected.
Studies involving preincubation of virus or cells with lactoferrin suggested that the protein does not bind to the virus, but rather blocks HS-
moieties on the cell surface. Charge-modified human serum albumin, with a net positive charge, had a similar antiviral effect against HS-
adapted SIN and SFV, suggesting that the antiviral activity of lactoferrin is related to its positive charge. It is concluded that human lactoferrin
inhibits viral infection by interfering with virus-receptor interaction rather than by affecting subsequent steps in the viral cell entry or
replication processes.
D 2005 Elsevier Inc. All rights reserved.
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Human lactoferrin (hLF) is an 80-kDa cationic glyco-
protein belonging to the transferrin family of Fe3+-trans-
porting proteins (see Kanyshkova et al., 2001 for review).
hLF is produced by epithelial cells and, as a result, is present
in mucosal secretions such as tears, saliva, nasal exudate,
gastrointestinal fluids, and seminal and vaginal fluids.
Furthermore, hLF is present in high concentrations in
human breast milk. Breast-feeding is known to protect
newborns against a variety of infections including viral0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.01.010
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1 Both authors contributed equally to this work.infections (Hanson and Korotkova, 2002). Viruses against
which lactoferrin possesses antiviral activity include human
herpes simplex virus types 1 and 2 (Hasegawa et al., 1994),
adenovirus (Arnold et al., 2002), human immunodeficiency
virus (Harmsen et al., 1995; Puddu et al., 1998; Swart et al.,
1999), hepatitis C virus (Ikeda et al., 2000), human
cytomegalovirus (Harmsen et al., 1995; Hasegawa et al.,
1994; Swart et al., 1999), poliovirus (Marchetti et al., 1999),
hantavirus (Murphy et al., 2000), and enterovirus 71 (Lin et
al., 2002) (for a review, see van der Strate et al., 2001).
Most of the above studies on the antiviral activity of hLF
suggest that the protein inhibits virus entry into cells rather
than later phases of viral replication. Lactoferrin, in
principle, can prevent virus cell entry by binding to the
virus particle or by binding to cell-surface molecules that05) 284–292
Fig. 1. Effect of hLF on infectivity of SIN TR339, SIN TRSB, and SFV.
CHO-K1 cells were pre-incubated with medium containing 200 Ag/ml hLF
or with medium alone. Each virus was titrated on the cells in the presence or
absence of 200 Ag/ml hLF. The average titers in the presence of hLF,
determined from two dilutions plated in duplicate, are presented as a
percentage of the average titer in the absence of hLF.
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lactoferrin would prevent viral attachment to the cell surface
(Meijer et al., 2001; van der Strate et al., 2001). It has been
suggested that binding of hLF to cell-surface heparan sulfate
glycosaminoglycans (HSPGs) is involved in inhibition of
viral infection (van der Strate et al., 2001). Numerous
studies have shown that viruses from different families
interact with HSPGs. Examples include Sindbis virus
(Byrnes and Griffin, 1998; Klimstra et al., 1998), Venezue-
lan equine encephalitis virus (Bernard et al., 2000), Ross
River virus (Heil et al., 2001), adeno-associated virus type 2
(Summerford and Samulski, 1998), foot-and-mouth disease
virus (Jackson et al., 1996; Sa-Carvalho et al., 1997),
herpesviruses (Birkmann et al., 2001; Compton et al., 1993;
Shukla and Spear, 2001; Trybala et al., 2002), human
immunodeficiency virus (Patel et al., 1993), echovirus
(Goodfellow et al., 2001), dengue virus (Chen et al.,
1997; Germi et al., 2002; Hilgard and Stockert, 2000),
and yellow fever virus (Germi et al., 2002). It is important to
note that the ability of viruses to interact with HSPGs is
often acquired by cell culture adaptation. However, affinity
for HSPGs has also been demonstrated in clinical isolates,
e.g., for Herpes Simplex virus type 1 (Trybala et al., 2002)
and echovirus (Goodfellow et al., 2001).
In order to determine whether hLF indeed exerts
antiviral activity through interference with virus binding
to HSPG receptors, we studied the effects of hLF on the
cell entry and receptor binding of alphaviruses, which are
adapted to interaction with HSPGs. Alphaviruses are
enveloped positive-strand RNA viruses belonging to the
family Togaviridae (reviewed by Strauss and Strauss,
1994). Cell entry of alphaviruses is mediated by the
heterodimeric E1/E2 envelope glycoprotein (Kielian,
1995). Infection of a host cell is initiated by the interaction
of the E2 glycoprotein with an attachment receptor on the
cell surface (Davis et al., 1986; McKnight et al., 1996;
Russel et al., 1989; Tucker et al., 1997), after which the
receptor-bound virion is internalized through endocytosis.
This is followed by E1-mediated fusion of the viral
envelope with the endosomal membrane, which delivers
the viral RNA to the cytosol (Helenius et al., 1980; Marsh
et al., 1982, 1983). For Sindbis virus (SIN), Klimstra et al.
(1998) identified positively charged amino acid substitu-
tions in the viral spike protein E2 after passaging of the
virus on BHK-21 cells. These mutations are responsible for
interaction of the virions with heparan sulfate (HS) moieties
of HSPGs.
In the present study, the antiviral activity of hLF on an
HS-adapted SIN mutant (TRSB), a non-adapted SIN strain
(TR339), and tissue-culture-adapted Semliki Forest virus
(SFV) was determined. Using a model system involving
liposomes containing lipid-conjugated heparin (HepPE) as
an attachment receptor analog for the virus (Smit et al.,
2002), we demonstrate that hLF prevents infection of cells
by alphaviruses through blocking of the viral attachment
receptors on the cell surface.Results
Inhibition of HS-adapted SIN and SFV infection by hLF
To determine whether hLF has antiviral activity against
HS-adapted alphaviruses, we performed a plaque titration in
the presence of hLF. CHO cells were pre-incubated with 200
Ag/ml hLF. The same concentration of hLF was maintained
throughout the infection and in the overlay. The cells were
infected with SIN strains TR339 and TRSB, and a
laboratory-adapted strain of SFV. TR339 is a non-HS-
adapted SIN strain, whereas TRSB and the laboratory strain
of SFV are known to use HS as a cell-attachment receptor
(Klimstra et al., 1998; Smit et al., 2002). Infection of CHO
cells by the SIN strain TR339 was not inhibited by hLF
(Fig. 1, black bar). By contrast, in the presence of hLF the
plaque titer of the HS-adapted SIN strain TRSB was
strongly reduced (Fig. 1, gray bar). The laboratory strain
of SFV was also strongly inhibited by hLF (Fig. 1, white
bar). No cytotoxic effect of hLF on the cells was observed
during the experiments.
The above results were confirmed by the use of
recombinant SFV carrying the LacZ gene. The virus was
derived from an SFV clone generated from a laboratory
strain passaged on BHK cells (Liljestro¨m and Garoff, 1991;
Liljestro¨m et al., 1991). In the presence of 200 Ag/ml hLF,
infection of BHK-21 cells by SFV-LacZ was completely
abolished (Fig. 2). A standard cytotoxicity assay excluded
the possibility that hLF was cytotoxic to the cells. In
addition, hLF did not change the pH of the medium
significantly up to a concentration of 2.5 mg/ml (not
shown).
Taken together, the results shown in Figs. 1 and 2 clearly
demonstrate that hLF inhibits the infection of cells by HS-
Fig. 3. Effect of hLF on binding of SIN TRSB and SFV to BHK-21 cells.
Monolayers were incubated with radiolabeled virus in the presence of hLF
at the indicated final concentrations at 4 8C. Unbound virus was removed
by washing of the cells with ice-cold buffer and bound virus was quantified
by liquid-scintillation counting of trypsinized cells. The amount of bound
virus is given as percentage of initially added virus. SIN TRSB, black bars;
SFV, white bars. Averages of six measurements per hLF concentration are
given. Error bars indicate standard deviations.
Fig. 2. Effect of hLF on infection of cells with recombinant SFV-LacZ
particles. BHK-21 cells were pre-incubated with medium containing 200 Ag/
ml hLF or with medium alone. The cells were infected with the same dilution
of SFV-LacZ particles in medium with or without 200 Ag/ml hLF. Only
infected cells express the LacZ gene, and are stained blue. Top panel:
infection in the absence of hLF (); bottom panel: infection in the presence of
200 Ag/ml hLF(+).
B.-L. Waarts et al. / Virology 333 (2005) 284–292286adapted SIN or SFV, whereas non-adapted SIN remains
unaffected.
Inhibition of binding of SIN TRSB and SFV to BHK-21 cells
by hLF
To determine whether the inhibitory action of hLF shown
in Figs. 1 and 2 is exerted by prevention of binding of the
HS-adapted viruses to cells, cell-binding experiments were
carried out with BHK-21 cells as described earlier (Byrnes
and Griffin, 1998; Klimstra et al., 1998; Smit et al., 2001).
Radiolabeled virus was allowed to bind to cells at 4 8C in
the presence of various concentrations of hLF. Unbound
virus was removed by washing, and bound virus was
quantified by liquid-scintillation counting of trypsinized
cells. Fig. 3 shows that binding of the HS-adapted SIN strain
TRSB to BHK-21 cells was inhibited by hLF in a dose-
dependent manner. Cell binding of laboratory-adapted SFV
was even more strongly inhibited by hLF.
Next, we attempted to determine whether hLF interferes
with virus-cell binding through interaction with the virus or
with the cells. To this end, we first pre-incubated SIN TRSB
with 200 Ag/ml hLF in a small volume. Before addition to
the cell monolayer, the mixture was diluted in medium
resulting in a final concentration of 0.7 Ag/ml hLF. As a
control, binding studies were performed with TRSB in thepresence of 200 Ag/ml or 0.7 Ag/ml hLF or in the absence of
hLF. Fig. 4A shows that pre-incubation of virus with 200
Ag/ml hLF did not inhibit cell binding of TRSB, whereas
200 Ag/ml hLF when present throughout the assay reduced
cell binding to about 45% of the level of binding observed
in the absence of hLF, consistent with the results shown in
Fig. 3. At a final concentration of 0.7 Ag/ml, hLF did not
inhibit cell binding of TRSB. These results suggest that hLF
does not bind to the virus, although the possibility cannot be
excluded that virus-bound hLF dissociates upon dilution of
virus preincubated in the presence of 200 Ag/ml. To
determine whether hLF binds to the cells, we pre-incubated
cell monolayers with medium containing 200 Ag/ml hLF.
After washing of the cells, TRSB was allowed to bind to the
cells. As a control, cells were either not treated with hLF or
hLF was present during the entire binding assay (Fig. 4B).
The results show that TRSB binding was not inhibited by
preincubation of the cells with 200 Ag/ml hLF. Only when
hLF was present throughout the assay TRSB binding was
inhibited. In this experiment, hLF was probably removed
during the washing of the cells. Therefore, although
suggestive of binding of hLF to the cells rather than to the
virus, the results of this experiment are not entirely
conclusive.
Effect of hLF on TRSB binding to HepPE-containing
liposomes
To further demonstrate that the inhibition of binding of
HS-adapted alphaviruses to cells by hLF does involve the
blocking of the HS moiety of the receptor, we employed
target liposomes containing lipid-conjugated heparin as a
model (Smit et al., 2002). Liposomes were pre-incubated
with various concentrations of hLF at 37 8C and pH 7.4.
Fig. 4. Effect of pre-incubation of TRSB or cells with hLF on cell binding. Panel A, radiolabeled TRSB virus was pre-incubated in a small volume medium
with 200 Ag/ml hLF (bar B) for 1 h at 4 8C. Subsequently, the mixture was diluted, such that the final concentration of hLF was 0.7 Ag/ml, and added to a
monolayer of BHK-21 cells at 4 8C. As a control, virus was pre-incubated with medium alone (bar A) or 200 Ag/ml hLF (bar C); alternatively, hLF at a
concentration of 0.7 Ag/ml was present in the medium throughout the binding assay (bar D). Panel B, BHK-21 cells were pre-incubated with medium alone
(bar A) or medium containing 200 Ag/ml hLF for 1 h at 4 8C (bar B). Subsequently, the cells were washed twice with buffer, and TRSB virus was added
and allowed to bind. As a control, 200 Ag/ml hLF was present in the medium during the binding assay (bar C). Unbound virus was removed by washing
the cells with ice-cold buffer and bound virus was quantified by liquid-scintillation counting of trypsinized cells. The amount of bound virus is given as
percentage of virus binding in the absence of hLF. In panel A, averages of 10 measurements are given; in panel B, averages of four measurements are
given. Error bars indicate standard deviations.
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of virus-liposome binding was determined in a sucrose-
density gradient flotation assay. Fig. 4 shows that in the
absence of hLF more than 60% of the TRSB particles bound
to the HepPE-containing liposomes (Fig. 4A, squares, and
Fig. 4B), while non-HS-adapted TR339 did not bind to
these liposomes to any significant extent (results not
shown). In agreement with earlier results (Smit et al.,
2002), there was no binding of TRSB virus to liposomes
lacking HepPE in the membrane (Fig. 4A, circles). Binding
of TRSB to HepPE-containing liposomes was inhibited by
hLF in a dose-dependent manner (Fig. 4B; IC50 = 0.12 AM).
These results show that binding of TRSB to liposomes at
neutral pH, which requires the presence of HepPE in the
target membrane (Smit et al., 2002), is inhibited by hLF.Fig. 5. Effect of hLF on SIN TRSB binding to HepPE-containing liposomes. R
(liposomes without HepPE). Liposomes were pre-incubated at 37 8C with hLF or w
virus was separated from unbound virus by flotation on a sucrose density-gradient
virus mixed with different liposomes. HepPE-containing liposomes, squares; lipos
of 80 Ag/ml hLF, triangles. Panel B shows the extent of virus binding to HepPE-
determined by sucrose density-gradient flotation analysis as shown in panel A.Alphavirus fusion with HepPE-containing liposomes is not
inhibited by hLF
Fusion of alphaviruses with liposomes has been studied
extensively in a model system in which fusion is monitored
on-line using virus labeled biosynthetically with a fluores-
cent pyrene lipid probe (reviewed in Smit et al., 2003). To
determine if hLF has an inhibitory effect on TRSB fusion,
the virus was mixed with HepPE-containing liposomes, and
fusion was triggered in the presence of hLF. As shown in
Fig. 5, hLF did not inhibit, and even slightly stimulated
(curves a–c), TRSB fusion at concentrations in excess of the
concentrations that strongly inhibit TRSB binding (Fig. 4B).
These results, indicating that TRSB fusion is not inhibited
by hLF, suggest that the antiviral action of hLF is onlyadiolabeled virus was mixed with HepPE-containing liposomes or control
ith buffer alone before being mixed with radiolabeled virus at 37 8C. Bound
as described in Materials and methods. Panel A shows gradient profiles of
omes without HepPE, circles; HepPE-containing liposomes in the presence
containing liposomes as a function of the hLF concentration. Binding was
Fig. 6. Effect of hLF on SIN TRSB fusion with HepPE-containing
liposomes. Virus and liposomes were mixed in buffer containing different
concentrations hLF at 37 8C. Fusion was triggered by lowering the pH and
was monitored continuously. curve a, 25 Ag/ml hLF; curve b, 50 Ag/ml
hLF; curve c, 200 Ag/ml hLF; curve d, no hLF.
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attachment step.
Inhibitory effect of positively charged human serum
albumin
The cationic character of hLF has recently been shown to
be of importance for its antiviral activity against CMV
(Beljaars et al., 2004). To determine whether the inhibition
of receptor interaction of HS-adapted alphaviruses by hLF is
also related to the positive charge of hLF, the effect of
positively charged human serum albumin (HSA) on TRSB
binding to HepPE-containing liposomes was studied. Fig. 7
shows that native HSA had no significant effect on TRSB
binding to HepPE-containing liposomes. Introduction of a
net positive charge into HSA results in a potent inhibitory
effect on TRSB binding to HepPE-containing liposomes
(Fig. 7). These findings indicate that the net positive charge
of hLF may well play an important role in the inhibitory
effect of the protein on virus binding to HS-moieties on cells
or to HepPE-containing liposomes.Discussion
In this paper, we studied the antiviral action of hLF. To
determine the mechanism of antiviral activity we used
alphaviruses adapted to HSPG as the attachment receptor
(Klimstra et al., 1998, Smit et al., 2002). hLF strongly
inhibited infection of cells by HS-adapted alphaviruses but
did not inhibit infection by the non-adapted SIN strain
TR339 (Fig. 1). At a concentration of 200 Ag/ml, hLF
caused a 70% reduction in viral plaques for TRSB, 90%
reduction for SFV, and no reduction for SIN TR339. The
antiviral action of hLF appeared to be exerted at the level of
cell attachment because the protein interfered with virus-cell
binding. TRSB showed residual binding to BHK cells in the
presence of high concentrations of hLF. No residual binding
of TRSB to HepPE-liposomes was observed, which contain
solely the HepPE receptor analog. This observation suggests
that TRSB is able to bind to other receptors on BHK cells
that are not blocked by hLF.
The use, in the present study, of a model system
consisting of liposomes with lipid-conjugated heparin
(HepPE) as a specific receptor analog (Smit et al., 2002)
provided compelling evidence for the notion that hLF
interferes with binding of HS-adapted SIN or SFV to HS-
moieties on cellular HSPGs. Indeed, hLF inhibited binding
of HS-adapted SIN and SFV with HepPE-containing
liposomes in a dose-dependent manner. By contrast, hLF
did not inhibit low-pH-induced virus fusion with HepPE-
containing liposomes, suggesting that hLF acts only at the
initial step of viral cell entry, that is, the attachment step as
opposed to the subsequent fusion of the viral envelope.
Interestingly, hLF, under the conditions of the experiment
shown in Fig. 6, even caused a small but consistentenhancement of the extent of fusion of SIN TRSB with
HepPE-containing liposomes. Such an increase of fusion
was not observed with target liposomes lacking HepPE
(results not shown). The most likely explanation is that
binding of the virus to HepPE at neutral pH restrains, to
some extent, subsequent productive interaction of the virus
with the target membrane at low pH; hLF, by preventing
virus binding to HepPE would remove this restraint, thus,
causing an apparent increase in the extent of fusion.
Whereas hLF has been shown to bind to certain viruses
and block viral entry in this manner (Marchetti et al., 1996;
van der Strate et al., 2001), the antiviral activity of hLF
against HS-adapted alphaviruses probably does not involve
binding to the virus particles. Firstly, the results in Fig. 4A
suggest that hLF does not bind to TRSB because pre-
incubation of TRSB with 200 Ag/ml hLF was not inhibitory
for virus binding (Fig. 4A). Secondly, the infection of cells
by SIN strain TR339 is not inhibited by hLF (Fig. 1), while
the receptor binding protein E2 of TRSB differs from that of
TR339 only by one amino acid substitution (Klimstra et al.,
1998,1999). This substitution results in a gain of one
positive charge for TRSB relative to TR339. It is very
unlikely that the increased positive charge of TRSB will
result in binding of a cationic protein, such as hLF, to the
virus.
Our results are consistent with other studies that have
shown that hLF is able to bind to heparin and HS. Binding
appears to be mediated by two clusters of basic residues
located within the first 33 residues of hLF (Mann et al.,
1994; van Berkel et al., 1997; Wu et al., 1995; Yazidi-
Belkoura et al., 2001). The cluster of Arg residues in the
first six amino acids of hLF (GRRRRS) is found to be
mainly responsible for the interaction with glycosamino-
glycans and may act synergistically with the second cluster
(RKVR) located at position 28–31 to form the predominant
glycosaminoglycan binding site of the protein. HSPGs are
present on the cell surface of most eukaryotic cells. The
glycosaminoglycan moiety HS of HSPGs is a highly
B.-L. Waarts et al. / Virology 333 (2005) 284–292 289sulfated disaccharide polymer and therefore possesses a net
negative charge. Proteoglycans have a large variety of
biological functions that are mediated by their glycosami-
noglycan moieties (for reviews see Tumova et al., 2000 and
Bernfield et al., 1999). Interaction of viruses with HS is
often the result of tissue-culture adaptation, as has been
reported for several viruses (Bernard et al., 2000; Heil et al.,
2001; Jackson et al., 1996; Klimstra et al., 1998; Sa-
Carvalho et al., 1997). However, for other viruses the ability
to bind HS has also been shown to be a feature of clinical
isolates (Goodfellow et al., 2001; Trybala et al., 2002). It
remains to be shown that clinical isolates of other viruses
also have HS binding capacity. Therefore, the study of hLF-
mediated interference of HS binding of viruses may well
contribute to the accumulating knowledge about the
potential of hLF as an antiviral agent.
Marchetti et al. (1996) studied the antiviral activity of
lactoferrins on HSV-1 and proposed, consistent with our
present results, that lactoferrins block cell receptors for
HSV-1, including HSPGs. Our results are also in agree-
ment with the recent findings by Di Biase et al. (2003),
who showed that mixtures of bovine lactoferrin and
heparin abolished the anti-adenovirus effect of each
compound alone and concluded that the anti-adenovirus
activity of bovine lactoferrin involves blocking cell-surface
HSPGs.
Cationic HSA (cat-HSA) also inhibited TRSB binding to
HepPE-containing liposomes. This suggests that the anti-
viral activity of hLF may well be related to its positive
charge. As shown in Fig. 7, the binding of TRSB was
inhibited at concentrations of cat-HSA that are lower than
the inhibitory concentrations of hLF, the IC50 values of cat-
HSA and hLF being 0.03 AM and 0.12 AM, respectively.
Structural features of the proteins are probably involved in
this difference, since the isoelectric points of cat-HSA and
hLF are similar (pI ~ 8). Overall, our results are in
agreement with the recent observations of Beljaars et al.Fig. 7. Effect of HSA and positively charged HSA (cat-HSA) on SIN TRSB
binding to HepPE-containing liposomes. Liposomes were pre-incubated at
37 8C with increasing concentrations of HSA (circles) or cat-HSA (squares)
before being mixed with radiolabeled virus at 37 8C. The extent of virus
binding to HepPE-containing liposomes as a function of HSA or cat-HSA
concentration is shown. Binding was determined by sucrose density-
gradient analysis as described in Materials and methods.(2004), who demonstrated the importance of the cationic
character of lactoferrin in inhibiting viral infection of host
cells with CMV, another HS-interacting virus.
In conclusion, the results in this paper demonstrate that
one way by which lactoferrin may inhibit infection of cells
by certain viruses is through blocking of HSPG virus
receptors on the cell surface.Materials and methods
Viruses
SIN TR339, SIN TRSB, and SFV-LacZ were generated
from cDNA clones. Construction of the consensus SIN
AR339 clone pTR339 and the HS-adapted SIN clone
pTRSB has been described previously (Klimstra et al.,
1998, 1999; McKnight et al., 1996). Construction of
pSFV3-LacZ, a recombinant construct based a clone
generated from a laboratory strain of SFVadapted to growth
on BHK-21 cells, has also been described previously
(Liljestro¨m and Garoff, 1991). SIN TR339 and SIN TRSB
seed viruses were produced by high-efficiency electro-
poration of BHK-21 cells with in vitro RNA transcripts of
linearized cDNA. SFV-LacZ was produced by co-electrop-
ration of pSFV3-LacZ RNA and pSFV-Helper1 RNA
(Liljestro¨m et al., 1991). TR339 and TRSB viruses were
used for preparation of virus stocks and for further
production of radiolabeled or fluorescently-labeled viruses,
as described below; SFV-LacZ was purified from the
supernatant of electroporated cells by sucrose-density
gradient centrifugation and used as such. A plaque-purified
tissue-culture-adapted strain of SFV was a generous gift of
Dr. Margaret Kielian (Albert Einstein College of Medicine,
Bronx, NY).
Replication-competent viruses were propagated on
BHK-21 cells. The cells were cultured in Glasgow’s
modification of Eagle’s minimal essential medium (Invi-
trogen, Breda, The Netherlands), supplemented with 5%
fetal calf serum, 10% tryptose phosphate broth, 200 mM
glutamine, 25 mM HEPES, and 7.5% sodium bicarbonate
(BHK-medium) at 37 8C and 5% CO2. Viruses released
from the cells at 20-hr post-infection were harvested, and
the stocks were subsequently used for production of pyrene-
or [35S]methionine-labeled SIN or SFV particles, as
previously described (Bron et al., 1993; Smit et al., 1999).
The viruses were characterized by plaque assay on BHK-21
cells (Klimstra et al., 1998), phospholipid analysis (Bo¨ttcher
et al., 1961), and protein determination (Peterson, 1977).
The purity of the viruses was confirmed by SDS-PAGE
analysis.
Proteins
hLF was obtained from Numico Research BV (Wage-
ningen, The Netherlands), HSA was purchased from the
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(Amsterdam, The Netherlands). Cat-HSA was prepared as
described previously (Swart et al., 1999).
Liposomes
Liposomes (large unilamellar vesicles) consisted of
phosphatidylcholine (PC), phosphatidylethanolamine (PE),
sphingomyelin (SPM), and cholesterol (Chol) in a molar
ratio of 0.83; 0.83; 0.83; 1.25, supplemented with 0.02
mol% HepPE (binding experiments) or 0.01 mol% HepPE
(fusion experiments) based on total phospholipid. The
phospholipids and cholesterol were obtained from Avanti
Polar Lipids (Alabaster, AL). The HepPE conjugate,
consisting of heparin (from porcine intestinal mucosa;
average molecular weight, 10,000; Scientific Protein Labo-
ratories, Wannakee, WI) coupled to dipalmitoyl-PE, was
synthesized and purified as described previously (Sugiura et
al., 1993). The liposomes were prepared by dialysis in the
presence of n-octyl-h-d-glucopyranoside (OGP; Calbio-
chem, Darmstadt, Germany), followed by a freeze–thaw and
extrusion procedure as described previously (Smit et al.,
2002).
Infectivity assays
Virus entry was determined by plaque formation or
LacZ gene expression. For the plaque assay, monolayers of
CHO-K1 cells were grown in 12-well plates at 37 8C, 5%
CO2 in HAM’s F12 medium with l-glutamine (Invitrogen,
Breda, The Netherlands) supplemented with 10% fetal calf
serum. The monolayers were pre-incubated for 1–1.5 h
with 200 Ag/ml hLF in medium or with medium alone.
Serial dilutions of virus in 0.6 ml of medium containing
200 Ag/ml hLF or medium alone were added to the cell
monolayers. After 1 h at 37 8C, the virus-containing
medium was removed from the monolayers and the cells
were washed 3 times with PBS. The washed monolayers
were overlaid with a 1:1 dilution of medium with or
without 400 Ag/ml hLF and a 2% aqueous solution of
methylcellulose (Sigma). After 2–3 days of incubation at
37 8C, the plaques were counted.
For the infection assay with recombinant SFV, mono-
layers of BHK-21 cells were grown in 24-well plates in
BHK-medium (see above). The monolayers were pre-
incubated for 1–1.5 h with 200 Ag/ml hLF in medium or
with medium alone at 37 8C. After removal of the medium,
0.3 ml per well of a dilution of recombinant SFV-LacZ virus
was added. The virus was diluted in medium with or without
200 Ag/ml hLF. After 1-h incubation at 37 8C, 5% CO2 the
virus solution was removed and the monolayers were
washed 2–3 times with PBS and 1 ml of medium with or
without 200 Ag/ml hLF was added and incubated overnight
at 37 8C, 5% CO2. Subsequently, the cells were washed
once with PBS and fixed for 5 min at room temperature with
a fresh mixture of 2% paraformaldehyde, 0.2% glutaralde-hyde in PBS with Ca2+ and Mg2+. Following this, the cells
were washed once with PBS and incubated for 2 h at 37 8C
with 0.1% 5V-bromo-4-chloro-3-indolyl-h-d-galactopyrano-
side (X-Gal) (Roche Diagnostics, Almere, The Nether-
lands), 5 mM K4[Fe(CN)6, 5 mM K3[Fe(CN)6], 2 mM
MgCl2, 0.15 mM NaCl, and 25 mM HEPES (Sigma).
Transfected cells appeared as blue cells.
Binding assays
Virus binding to BHK-21 cells was performed essentially
as described previously (Byrnes and Griffin, 1998; Klimstra
et al., 1998; Smit et al., 2001). Cells were grown in 12-well
plates in BHK-medium at 37 8C, 5% CO2. At 4 8C, the
medium was removed from the cells, which were then
washed twice with ice-cold HNE supplemented with 0.5 mM
CaCl2–0.5mMMgCl2–1%FCS (HNE*). Approximately 10
4
cpm of [35S]methionine-labeled virus was added to each well
in 150 Al of HNE* containing various concentrations of hLF.
Subsequently, the plates were rocked for a period of 1.5–2 h at
4 8C. The virus suspension was removed and the cells were
washed twice with ice-cold HNE*. Cells were trypsinized
and collected after which virus binding was quantified by
liquid-scintillation counting.
Virus binding to liposomes was assessed by a coflo-
tation assay, as described previously (Smit et al., 2002,
2003). Briefly, liposomes (200 AM) were incubated in 5
mM HEPES, 150 mM NaCl, and 0.1 mM EDTA (pH 7.4)
(HNE) containing various concentrations of hLF, HSA, or
cat-HSA for 10 min at 37 8C, after which [35S]methionine-
labeled virus (ranging from 105 to 106 cpm) was added to
the mixture and allowed to incubate for another 10 min at
37 8C. Then, 0.1 ml of the mixture was added to 1.4 ml of
50% (w/v) sucrose in HNE, and this was layered on a
cushion of 0.5 ml of 60% (w/v) sucrose in HNE. On top of
this, 1.0-ml volumes of 35, 20, and 5% (w/v) sucrose in
HNE were layered. After centrifugation at 4 8C for 2 h at
150,000  g in a Beckman SW50 rotor, the gradient was
fractionated into 10 samples, starting from the top. The
radioactivity found in the top four fractions, relative to the
total amount of radioactivity, was taken as a measure of
virus-liposome binding.
Fusion assay
Fusion of pyrene-labeled SIN-TRSB with HepPE lip-
osomes was performed as described elsewhere (Smit et al.,
2002, 2003). Virus and liposomes were mixed in HNE
containing different concentrations of hLF in a magnetically
stirred and thermostatted (37 8C) quartz cuvette in an AB2
fluorometer (SLM/Aminco, Urbana, IL). Fusion was trig-
gered by injecting a small volume of 0.1 M MES (Sigma),
0.2 M acetic acid, pretitrated with NaOH to achieve pH 5.0.
Fusion was monitored continuously as a decrease in pyrene
excimer fluorescence (excitation at 345 nm and emission at
480 nm) by dilution of the lipid probe from the viral
B.-L. Waarts et al. / Virology 333 (2005) 284–292 291membrane into the target membrane. The fusion scale was
calibrated such that 0% fusion corresponded to the initial
excimer fluorescence intensity and 100% fusion to complete
dilution of the probe.
Toxicity assay
The cytotoxicity of human lactoferrin on BHK-21 cells
was tested according to standard methods using the cell
proliferation reagent 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-
(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt
(WST-1) (Roche Diagnostics, Almere, The Netherlands).
On day 1, cells were plated at 104 per well in 96-wells plates
in BHK-21 medium containing various concentrations of
human lactoferrin. On day 3, the medium was removed from
the cells, after which 10 Al of WST-1 reagent was added to
each well. After 1, 2, 3, and 4 h, the optical density (OD)
was measured at 450 nm.Acknowledgments
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